New pill tested to shrink painful NF1 tumors

NCT ID NCT06961565

Summary

This early-stage study is testing a new oral medication called PAS-004 in adults with Neurofibromatosis Type 1 (NF1) who have painful, inoperable, or recurring plexiform neurofibroma tumors. The main goals are to find a safe dose, understand the side effects, and see if the drug can reduce tumor size. Participants will take the pill daily for up to six months while doctors monitor their health closely.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMA PLEXIFORM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Royal North Shore Hospital

    RECRUITING

    St Leonards, New South Wales, 2065, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Severance Hospital, Yonsei University Health System

    RECRUITING

    Sinchŏn-dong, 6164, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35294, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.